References

Lucy C Chappell; Jennifer L Bell; Anne Smith; Catherine Rounding; Ursula Bowler; Louise Linsell; Edmund Juszczak; Sue Tohill; Amanda Redford; Peter H Dixon; Jenny Chambers; Rachael Hunter; Jon Dorling; Catherine Williamson; Jim G Thornton

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT. Southampton (UK): NIHR Journals Library; 2020 Dec. (Efficacy and Mechanism Evaluation, No. 7.9.)

Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT.

Show details

Contents

< Prev Next >

References

1.: Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet 2019;394:849–60. 10.1016/S0140-6736(19)31270-X [PMC free article: PMC6739598] [PubMed: 31378395] [CrossRef]
2.: Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet 2019;393:899–909. 10.1016/S0140-6736(18)31877-4 [PMC free article: PMC6396441] [PubMed: 30773280] [CrossRef]
3.: Puljic A, Kim E, Page J, Esakoff T, Shaffer B, LaCoursiere DY, Caughey AB. The risk of infant and fetal death by each additional week of expectant management in intrahepatic cholestasis of pregnancy by gestational age. Am J Obstet Gynecol 2015;212:667.e1–5. 10.1016/j.ajog.2015.02.012 [PubMed: 25687562] [CrossRef]
4.: Carey EJ, Lindor KD. Current pharmacotherapy for cholestatic liver disease. Expert Opin Pharmacother 2012;13:2473–84. 10.1517/14656566.2012.736491 [PubMed: 23094715] [CrossRef]
5.: Roma MG, Toledo FD, Boaglio AC, Basiglio CL, Crocenzi FA, Sánchez Pozzi EJ. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci 2011;121:523–44. 10.1042/CS20110184 [PubMed: 21854363] [CrossRef]
6.: Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006;3:318–28. 10.1038/ncpgasthep0521 [PubMed: 16741551] [CrossRef]
7.: Bicocca MJ, Sperling JD, Chauhan SP. Intrahepatic cholestasis of pregnancy: review of six national and regional guidelines. Eur J Obstet Gynecol Reprod Biol 2018;231:180–7. 10.1016/j.ejogrb.2018.10.041 [PubMed: 30396107] [CrossRef]
8.: Saleh MM, Abdo KR. Consensus on the management of obstetric cholestasis: National UK survey. BJOG 2007;114:99–103. 10.1111/j.1471-0528.2006.01102.x [PubMed: 17081185] [CrossRef]
9.: Bacq Y, Sentilhes L, Reyes HB, Glantz A, Kondrackiene J, Binder T, et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 2012;143:1492–501. 10.1053/j.gastro.2012.08.004 [PubMed: 22892336] [CrossRef]
10.: Gurung V, Middleton P, Milan SJ, Hague W, Thornton JG. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst Rev 2013;6:. 10.1002/14651858.CD000493.pub2 CD000493 [PMC free article: PMC7043272] [PubMed: 23794285] [CrossRef]
11.: Chappell LC, Gurung V, Seed PT, Chambers J, Williamson C, Thornton JG, PITCH Study Consortium. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ 2012;344:e3799. 10.1136/bmj.e3799 [PMC free article: PMC3420230] [PubMed: 22695903] [CrossRef]
12.: Royal College of Obstetricians and Gynaecologists. Obstetric Cholestasis: Green-top Guideline No. 43. London: Royal College of Obstetricians and Gynaecologists; 2011.
13.: White SJ, Freedman LS. Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer 1978;37:849–57. 10.1038/bjc.1978.124 [PMC free article: PMC2009630] [PubMed: 350254] [CrossRef]
14.: Chappell LC, Chambers J, Dixon PH, Dorling J, Hunter R, Bell JL, et al. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve perinatal outcomes: protocol for a randomised controlled trial (PITCHES). Trials 2018;19:657. 10.1186/s13063-018-3018-4 [PMC free article: PMC6260710] [PubMed: 30482254] [CrossRef]
15.: Kahan BC, Morris TP. Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis. BMJ 2012;345:e5840. 10.1136/bmj.e5840 [PMC free article: PMC3444136] [PubMed: 22983531] [CrossRef]
16.: Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702–6. 10.1093/aje/kwh090 [PubMed: 15033648] [CrossRef]
17.: Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230–5. 10.1136/bmj.300.6719.230 [PMC free article: PMC1662068] [PubMed: 2106931] [CrossRef]
18.: NHS Improvement. Reference Costs 2017/18. URL: https://improvement.nhs.uk/resources/reference-costs (accessed 21 March 2019).
19.: Joint Formulary Committee. British National Formulary 17 ed. London: BMJ Group and Pharmaceutical Press; 2018.
20.: Department for Communities and Local Government. The English Indices of Deprivation 2015. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/465791/English_Indices_of_Deprivation_2015_-_Statistical_Release.pdf (accessed 30 August 2020).
21.: The Global Health Network. INTERGROWTH-21st: newborn size. URL: https://intergrowth21.tghn.org/newborn-size-birth/#c4 (accessed 25 September 2017).
22.: Herrera CA, Manuck TA, Stoddard GJ, Varner MW, Esplin S, Clark EAS, et al. Perinatal outcomes associated with intrahepatic cholestasis of pregnancy. J Matern Fetal Neonatal Med 2018;31:1913–20. 10.1080/14767058.2017.1332036 [PubMed: 28581354] [CrossRef]
23.: Brites D, Rodrigues CM, Oliveira N, Cardoso M, Graça LM. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J Hepatol 1998;28:91–8. 10.1016/S0168-8278(98)80207-9 [PubMed: 9537870] [CrossRef]
24.: Australian New Zealand Clinical Trials Registry. Trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study. URL: www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374510 (accessed 20 March 2019).
25.: Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014;59:1482–91. 10.1002/hep.26617 [PMC free article: PMC4296226] [PubMed: 23857305] [CrossRef]
26.: Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev 2020;7:. 10.1002/14651858.CD000493.pub3 CD000493 [PMC free article: PMC7389072] [PubMed: 32716060] [CrossRef]
27.: Schultz F, Hasan A, Alvarez-Laviada A, Miragoli M, Bhogal N, Wells S, et al. The protective effect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fibroblasts. Prog Biophys Mol Biol 2016;120:149–63. 10.1016/j.pbiomolbio.2016.01.003 [PubMed: 26777584] [CrossRef]
28.: Abu-Hayyeh S, Ovadia C, Lieu T, Jensen DD, Chambers J, Dixon PH, et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology 2016;63:1287–98. 10.1002/hep.28265 [PMC free article: PMC4869673] [PubMed: 26426865] [CrossRef]
29.: Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010;139:1008–18, 1018.e1. 10.1053/j.gastro.2010.05.009 [PubMed: 20546739] [CrossRef]
30.: ICP Support. ICP Research – What women think. [YouTube]. URL: www.youtube.com/watch?v=tLK5SgnpN6A%26t=51s (accessed 3 October 2020).

Copyright © Queen’s Printer and Controller of HMSO 2020. This work was produced by Chappell et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Bookshelf ID: NBK564943

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT. Southampton (UK): NIHR Journals Library; 2020 Dec. (Efficacy and Mechanism Evaluation, No. 7.9.) References.
PDF version of this title (1.6M)

Other titles in this collection

Efficacy and Mechanism Evaluation

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Recent Activity

Clear Turn Off Turn On

References - Ursodeoxycholic acid to reduce adverse perinatal outcomes for intra...
References - Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Ursodeoxycholic acid to reduce adverse perinatal outcomes for intrahepatic cholestasis of pregnancy: the PITCHES RCT.

References

Views

Other titles in this collection

Related information

Recent Activity